Compare Gartner Inc (IT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Gartner Inc trades at $197.82 (market cap $12.44B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Gartner Inc is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 65 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| IT | SYRE | |
|---|---|---|
Market Cap | $12.44B | $7.52B |
Volume | 818,587 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $258.17 | $108.92 |
52-Week Low | $125.68 | $22.18 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $14.18B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner Inc. (IT) trades at $195.77, up 0.86% on the day, with a bullish technical signal and strong profitability metrics including a 69.63% gross margin and 113.58% ROE. Recent earnings beats and positive news flow around AI advisory demand support the stock, though net cash flow turned negative in 2025. The current price sits above the consensus target of $178.14, indicating potential overvaluation concerns among analysts.
Outlook remains positive due to robust contract value growth and AI-driven demand, but risks include volatile cash flows, high P/B ratio of 160.06, and a shareholder investigation. Investor sentiment is mixed with 55.55% hold ratings, suggesting cautious optimism amid execution risks and macroeconomic uncertainty.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
